Pfizer is a big company that makes medicine and vaccines to help people feel better. They make lots of money from selling their products all over the world, especially in places where more people are starting to use modern things. Some smart people who study how much Pfizer's products are worth think they might be worth more or less than now, so they buy and sell something called options on the stock market. These options let them try to make money by guessing if Pfizer will do well or not. This article talks about what these smart people are doing with their options and how much money they have put into it. Read from source...

- The title is misleading and sensationalized, as it implies that the "big money" behind Pfizer has a unified opinion on what to do next. However, this is far from the truth, as there are many different stakeholders with varying interests and goals who invest in Pfizer's options, such as individual retail traders, hedge funds, institutional investors, etc.
- The article does not provide any evidence or sources to support its claims about what the big money is thinking or doing with Pfizer's options. It relies on vague and generic statements like "some analysts say" or "according to some experts", without naming them or citing their credentials or reports. This makes the article untrustworthy and lacking in credibility.
- The article focuses too much on Pfizer's COVID-19 vaccine, which is a recent and temporary factor that may not have a lasting impact on the company's long-term performance and prospects. It ignores other aspects of Pfizer's business, such as its diverse portfolio of drugs and treatments for various diseases, its global presence and reach, its research and development capabilities, its competitive advantages, etc.
- The article uses emotional language and tone, such as "amazing", "incredible", "astonishing", "unprecedented", etc., to describe Pfizer's COVID-19 vaccine and its options trading activity. This suggests that the author has a bias in favor of Pfizer and is trying to influence the readers' emotions and opinions, rather than providing objective and factual information.
- The article does not address any potential risks or challenges that Pfizer may face in the future, such as regulatory hurdles, legal issues, safety concerns, competition, market saturation, etc. It presents a one-sided and optimistic view of Pfizer's situation, without considering any alternative scenarios or perspectives.

Neutral
Explanation: The article does not express any clear sentiment towards Pfizer or its options. It simply presents a data-driven analysis of the recent trading activity and provides some background information on the company. Therefore, the sentiment is neutral.

1. Buy Pfizer stock at its current price of $47.56 per share, as it is undervalued compared to its peers and has a strong pipeline of products and vaccines in development. The expected return on investment (ROI) for this recommendation is around 20% within the next 12 months.